Oncology and Hematology

Episodes 33-48 of 72

• 

  RestartResume

  Managing Myelofibrosis-Associated Anemia

  RestartResume

  Managing Myelofibrosis-Associated Anemia

  MinuteCE®

  Managing Myelofibrosis-Associated Anemia

  1.00 program credit

  • 

    

    Gabriela Hobbs, MD

  1.00 program credit

• 

  RestartResume

  Case Discussion: What JAK Inhibitor Should I Use in a Transfusion-Dependent Patient With MF With Platelets > 50 × 10⁹/L?

  RestartResume

  Case Discussion: What JAK Inhibitor Should I Use in a Transfusion-Dependent Patient With MF With Platelets > 50 × 10⁹/L?

  MinuteCE®

  Case Discussion: What JAK Inhibitor Should I Use in a Transfusion-Dependent Patient With MF With Platelets > 50 × 10⁹/L?

  1.00 program credit

  • 

    

    John Mascarenhas, MD

  • 

    

    Gabriela Hobbs, MD

  1.00 program credit

• 

  RestartResume

  Managing Treatment-Related Toxicities With JAK Inhibitor Therapy in Myelofibrosis

  RestartResume

  Managing Treatment-Related Toxicities With JAK Inhibitor Therapy in Myelofibrosis

  MinuteCE®

  Managing Treatment-Related Toxicities With JAK Inhibitor Therapy in Myelofibrosis

  1.00 program credit

  • 

    

    John Mascarenhas, MD

  1.00 program credit

• 

  RestartResume

  Pacritinib for Myelofibrosis Across the Cytopenic Spectrum

  RestartResume

  Pacritinib for Myelofibrosis Across the Cytopenic Spectrum

  MinuteCE®

  Pacritinib for Myelofibrosis Across the Cytopenic Spectrum

  1.00 program credit

  • 

    

    John Mascarenhas, MD

  1.00 program credit

• 

  RestartResume

  Treatment Options for Ruxolitinib Intolerance or Resistance in Myelofibrosis

  RestartResume

  Treatment Options for Ruxolitinib Intolerance or Resistance in Myelofibrosis

  MinuteCE®

  Treatment Options for Ruxolitinib Intolerance or Resistance in Myelofibrosis

  1.00 program credit

  • 

    

    Gabriela Hobbs, MD

  1.00 program credit

• 

  RestartResume

  Managing Myelofibrosis-Associated Thrombocytopenia

  RestartResume

  Managing Myelofibrosis-Associated Thrombocytopenia

  MinuteCE®

  Managing Myelofibrosis-Associated Thrombocytopenia

  1.00 program credit

  • 

    

    Gabriela Hobbs, MD

  1.00 program credit

• 

  MinuteCE®

  Tailoring JAK Inhibitor Therapy in Patients With Myelofibrosis

  1.00 credit 10 episodes

  • 

    

    John Mascarenhas, MD

  • 

    

    Gabriela Hobbs, MD

  1.00 credit 10 episodes

• 

  RestartResume

  How to Use Prognostic Risk Scoring and Symptom Burden Assessment to Tailor Myelofibrosis Treatment

  RestartResume

  How to Use Prognostic Risk Scoring and Symptom Burden Assessment to Tailor Myelofibrosis Treatment

  MinuteCE®

  How to Use Prognostic Risk Scoring and Symptom Burden Assessment to Tailor Myelofibrosis Treatment

  1.00 program credit

  • 

    

    Gabriela Hobbs, MD

  1.00 program credit

• 

  RestartResume

  Improving Transfusion Independence With JAK Inhibitor Therapy

  RestartResume

  Improving Transfusion Independence With JAK Inhibitor Therapy

  MinuteCE®

  Improving Transfusion Independence With JAK Inhibitor Therapy

  1.00 program credit

  • 

    

    John Mascarenhas, MD

  1.00 program credit

• 

  RestartResume

  Case Consult: Treatment Options for an Unresectable HCC Patient Who Has Esophageal Varices

  RestartResume

  Case Consult: Treatment Options for an Unresectable HCC Patient Who Has Esophageal Varices

  MinuteCE®

  Case Consult: Treatment Options for an Unresectable HCC Patient Who Has Esophageal Varices

  1.00 program credit

  • 

    

    Aiwu Ruth He, MD, PhD

  1.00 program credit

• 

  MinuteCE®

  Unresectable Hepatocellular Carcinoma: Selecting the Optimal First-Line ICI Combination

  1.00 credit 10 episodes

  • 

    

    Aiwu Ruth He, MD, PhD

  • 

    

    Ghassan K. Abou-Alfa, MD

  1.00 credit 10 episodes

• 

  RestartResume

  Selecting the Optimal ICI Partner for First-Line Treatment of Unresectable HCC: CTLA-4 vs VEGFInhibitors

  RestartResume

  Selecting the Optimal ICI Partner for First-Line Treatment of Unresectable HCC: CTLA-4 vs VEGFInhibitors

  MinuteCE®

  Selecting the Optimal ICI Partner for First-Line Treatment of Unresectable HCC: CTLA-4 vs VEGFInhibitors

  1.00 program credit

  • 

    

    Ghassan K. Abou-Alfa, MD

  • 

    

    Aiwu Ruth He, MD, PhD

  1.00 program credit

• 

  RestartResume

  Emerging First-Line ICI Combination Regimens in Patients With Unresectable HCC

  RestartResume

  Emerging First-Line ICI Combination Regimens in Patients With Unresectable HCC

  MinuteCE®

  Emerging First-Line ICI Combination Regimens in Patients With Unresectable HCC

  1.00 program credit

  • 

    

    Ghassan K. Abou-Alfa, MD

  1.00 program credit

• 

  RestartResume

  Pivotal Data Supporting First-Line Atezolizumab/Bevacizumab in Unresectable HCC

  RestartResume

  Pivotal Data Supporting First-Line Atezolizumab/Bevacizumab in Unresectable HCC

  MinuteCE®

  Pivotal Data Supporting First-Line Atezolizumab/Bevacizumab in Unresectable HCC

  1.00 program credit

  • 

    

    Aiwu Ruth He, MD, PhD

  1.00 program credit

• 

  RestartResume

  Managing Adverse Events Associated With ICI Combinations in Patients With Unresectable HCC

  RestartResume

  Managing Adverse Events Associated With ICI Combinations in Patients With Unresectable HCC

  MinuteCE®

  Managing Adverse Events Associated With ICI Combinations in Patients With Unresectable HCC

  1.00 program credit

  • 

    

    Aiwu Ruth He, MD, PhD

  1.00 program credit

• 

  RestartResume

  Use of ICI Combination Regimens in Patients With Intermediate-Stage HCC

  RestartResume

  Use of ICI Combination Regimens in Patients With Intermediate-Stage HCC

  MinuteCE®

  Use of ICI Combination Regimens in Patients With Intermediate-Stage HCC

  1.00 program credit

  • 

    

    Ghassan K. Abou-Alfa, MD

  1.00 program credit